CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.
The Afirma GEC is a laboratory-developed test ordered by physicians who perform fine needle aspiration biopsies to evaluate thyroid nodules for potential cancer. Under the agreement, physician clients of Quest will be able to order the test on behalf of patients and refer patient specimens to Veracyte for genomic testing. Quest will make the service available through AmeriPath, the anatomic pathology business of Quest Diagnostics, for use on cytopathology results of these biopsies in cases when they are indeterminate.
Veracyte, 650-243-6300